NZ750271B2 - New use of n,n-bis-2-mercaptoethyl isophthalamide - Google Patents
New use of n,n-bis-2-mercaptoethyl isophthalamideInfo
- Publication number
- NZ750271B2 NZ750271B2 NZ750271A NZ75027117A NZ750271B2 NZ 750271 B2 NZ750271 B2 NZ 750271B2 NZ 750271 A NZ750271 A NZ 750271A NZ 75027117 A NZ75027117 A NZ 75027117A NZ 750271 B2 NZ750271 B2 NZ 750271B2
- Authority
- NZ
- New Zealand
- Prior art keywords
- pharmaceutically
- isophthalamide
- bis
- nbmi
- acceptable salt
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
Abstract
There is provided the compound N,N-bis-2-mercaptoethyl isophthalamide (NBMI), or a pharmaceuticaliy-acceptable salt and/or derivative thereof, for use in the treatment or prevention of paracetamol toxicity. Such compounds have particular utility in the treatment or prevention of acute liver failure associated with paracetamol toxicity.
Claims (4)
1. Use of N,N-bismercaptoethyl isophthalamide (NBMI), or a pharmaceutically- acceptable salt thereof, in the manufacture of a medicament for the prevention of paracetamol toxicity.
2. Use of N,N-bismercaptoethyl isophthalamide (NBMI), or a pharmaceutically- acceptable salt thereof, in the manufacture of a medicament for the prevention of acute liver failure associated with paracetamol toxicity.
3. A pharmaceutical formulation comprising: (a) N,N-bismercaptoethyl isophthalamide (NBMI), or a pharmaceutically- acceptable salt thereof; and (b) paracetamol, and optionally one or more pharmaceutically-acceptable excipients.
4. A kit-of-parts comprising components: (A) a pharmaceutical formulation comprising N,N-bismercaptoethyl isophthalamide (NBMI), or a pharmaceutically-acceptable salt thereof, and optionally one or more pharmaceutically-acceptable excipients; and (B) a pharmaceutical formulation comprising paracetamol, and optionally one or more pharmaceutically-acceptable excipients, wherein components (A) and (B) are formulated to be in a form that is suitable for administration in conjunction with the other.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB201613535 | 2016-08-05 | ||
| PCT/GB2017/052306 WO2018025049A1 (en) | 2016-08-05 | 2017-08-04 | New use of n,n-bis-2-mercaptoethyl isophthalamide |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NZ750271A NZ750271A (en) | 2025-07-25 |
| NZ750271B2 true NZ750271B2 (en) | 2025-10-29 |
Family
ID=
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SA520420033B1 (en) | Pharmaceutical compounds | |
| MY192084A (en) | Pyrazolo-heteroaryl derivative, preparation method and medical use thereof | |
| MX2022013612A (en) | Combinations of lsd1 inhibitors for the treatment of hematological malignancies. | |
| CL2018000318A1 (en) | Compounds derived from pyridinone, bromodomain inhibitors; pharmaceutical composition comprising them; and its use in the treatment of cancer diseases. (divisional application 201600925) | |
| WO2016134301A3 (en) | Neuroactive steroids, compositions, and uses thereof | |
| HRP20250119T1 (en) | A kdm1a inhibitor and its use in therapy | |
| CL2013002417A1 (en) | Compounds derived from fluoropyridinone; pharmaceutical composition comprising them; and its use in the treatment of bacterial infections. | |
| MX2020010300A (en) | Mono-(acid) salts of 6-aminoisoquinolines and uses thereof. | |
| MY179605A (en) | Use of benzimidazole-proline derivatives | |
| DOP2016000254A (en) | PHARMECEUTIC FORMULATIONS OF PAN-RAF QUINASE INHIBITOR, PROCEDURES FOR THEIR PREPARATION, AND METHODS OF USE. | |
| MX381440B (en) | PHARMACEUTICAL COMPOSITION FOR TREATMENT OF ULCERATIVE COLITIS. | |
| PH12018500377A1 (en) | Novel annelated benzamides | |
| MX2022003504A (en) | IRAQ INHIBITOR AND METHOD OF PREPARATION THEREOF AND USE THEREOF. | |
| NZ757526A (en) | Naphthoquinones, their derivatives and uses thereof in methods for the treatment of mitochondrial dysfunction | |
| PH12018500378B1 (en) | Novel annelated phenoxyacetamides | |
| IL276194B2 (en) | Compounds or pharmaceutical compositions comprising them for use in the treatment of paininhibiting | |
| EP4272832A3 (en) | Antimicrobial compounds, compositions, and uses thereof | |
| EA201891413A1 (en) | PHARMACEUTICAL COMPOSITION CONTAINING ANHYDROUS DAZATINIB | |
| AR114418A1 (en) | CYCLIC COMPOUND OF METHYLACTAM AND ITS PHARMACEUTICAL USE | |
| MX2017013099A (en) | Methods for the treatment of inflammatory disorders. | |
| MX2019009235A (en) | Anti-fibrotic compounds. | |
| IL264538B2 (en) | New use of n,n-bis-2-mercaptoethyl isophthalamide | |
| WO2017034242A3 (en) | Novel catechol derivative and pharmaceutical composition comprising same | |
| PH12020500436A1 (en) | Aromatic derivative, preparation method for same, and medical applications thereof | |
| NZ750271B2 (en) | New use of n,n-bis-2-mercaptoethyl isophthalamide |